Aminoguanidin ve Kardiyovasküler Sistem

Year 2012, Volume: 1 Issue: 2, 9 - 14, 01.10.2012

Hakan Parlakpınar Mehmet Hamdi Örüm Ahmet Acet

Abstract

Aminoguanidin AG , yüzyıldan uzun bir süredir bilinen, yapısal olarak L-Arjinin aminoasitine benzeyen, indüklenebilir nitrik oksit sentaz iNOS ’u selektif olarak inhibe eden, bu şekilde azalmış nitrik oksit NO oluşumuna neden olan bir bileşiktir. AG’nin önemli biyolojik etkileri geçtiğimiz yıllarda keşfedilmiştir. Keşfedilen ilk biyolojik etkisi, histamin, putreskin gibi aktif diaminlerin oksidatif deaminasyonunu katalizleyen, diamin oksidaz’ın inhibisyonudur. AG, etkili bir antioksidan ve serbest radikal süpürücüdür. AG hücre ve dokularda lipid peroksidasyonunun oluşumunu önler. Pek çok araştırmacı bu özellikleri üzerinden, AG’nin kardiyovasküler sistemdeki rolünü açıklamaya çalışmıştır. NO vasküler tonusun düzenlenmesi, endotel bütünlüğünün ve permeabilitesinin düzenlenmesi ve miyokard kontraktilitesinin düzenlenmesinde önemli bir rol oynar. Bu derlemede AG’nin kardiyovasküler sistem üzerindeki etkilerinin gözden geçirilmesi amaçlandı

Keywords

Aminoguanidin, Nitrik oksit, Kardiyovasküler sistem

Aminoguanidine and Cardiovascular System

Abstract

Aminoguanidine AG is a compound which has been known for over a century, structurally similar to L-arginine amino acid, a selective inhibitor of inducible nitric oxide synthase iNOS and in this way leads to reduced nitric oxide NO . Its important biological effects were discovered in recent years. The first discovered effect is the inhibition of diamine oxidase which catalyzes the oxidative deamination of biologically active deamines such as histamine and putrescine. AG is an effective antioxidant and free radical scavenger. AG prevents the formation of lipid peroxidation in cells and tissues. By using these characteristics, many investigators tried to explain the role of AG on the cardiovascular system. NO plays a major role in the regulation of vascular tone, endothelial integrity and permeability regulation and myocardial contractility. In this review, we aimed to summarize the effects of AG on the cardiovascular system

Keywords

Aminoguanidine, Nitric oxide, Cardiovascular system

References

• 1. Budavari S, O’Neil MJ, Smith A, Heckelman PE. In: Stecher PG. The Merck Index. 8th ed. Rahway; Merck & Co Inc: 1989. p.56.
• 2. Nilsson BO. Biological effects of aminoguanidine: an update. Inflamm Res 1999; 48(10): 509-15.
• 3. Ou P, Wolff SP. Aminoguanidine: a drug proposed for prophylaxis in diabetes inhibits catalase and generates hydrogen peroxide in vitro. Biochem Pharmacol 1993; 46(7): 1139-44.
• 4. Baynes JW, Thorpe SR. Glycoxidation and lipoxidation in atherogenesis. Free Radic Biol Med 2000; 28(12): 1708-16.
• 5. Yoshida T, Iwakiri R, Noda T, Okamoto K, Kojima M, Fukuyama K, et al. Histaminergic effect on apoptosis of rat small intestinal mucosa after ischemia reperfusion. Diges Dis Sci 2000; 45(6): 1138-44.
• 6. Özgüneş H, Atasayar S. Aminoguanidin ve Hastalıklardaki Onemi. Turkiye Klinikleri J Med Sci 2009; 29(4): 976-86.
• 7. Mansour M, Daba MH, Gado A, Al-Rikabi A, AlMajed A. Protective effect of L-arginine against nephrotoxicity induced by cyclosporine in normal rats. Pharmacol Res 2002; 45(6): 441-6.
• 8. Türker K, Kayaalp SO. Eikazonoidler ve Diğer Otokoidler. Kayaalp SO, Ed. Rasyonel Tedavi Yönünden Tıbbi Farmakoloji. 9. Baskı. Ankara; Hacettepe-Taş Kitapçılık Ltd Şti, 1998; 1513-48.
• 9. Lecour S, Maupoil V, Zeller M, Laubriet A, Briot T, Rochette L. Levels of nitric oxide in the heart after experimental myocardial ischemia. J Cardiovasc Pharmacol 2001; 37: 55–63.
• 10. Moncado S. The L-arginine: Nitric oxide pathway. Acta Physiology Scand 1992; 145(3): 201-27.
• 11. Nara K, Konno D, Uchida J, Kiuchi Y, Oguchi K. Protective effect of nitric oxide against ironinduced neuronal damage. Journal of Neural Transsmisssion 1999; 106: 835- 48.
• 12. Köse T. Deneysel diffüz beyin hasarında nitrik oksit sentetaz inhibitörü aminoguanidin’ in etkileri. Uzmanlık tezi, Isparta: 2006 (Bu tez Süleyman Demirel Üniversitesi Araştırma Fonu tarafından 1246-TU-06 proje numarası ile desteklenmiştir).
• 13. Morris SM Jr, Billiar TR. New insights into the regulation of inducible nitric oxide synthesis. Am J Physiol 1994; 266(6 Pt 1): 829-39.
• 14. Polat A, Parlakpinar H, Tasdemir S, Colak C, Vardi N, Ucar M, et al. Protective role of aminoguanidine on gentamicin-induced acute renal failure in rats. Acta histochemica 2006; 108: 365-71.
• 15. Yildiz G, Demiryurek AT, Sahin-Erdemli I, Kanzik I. Comparison of antioxidant activities of aminoguanidine, methyl-guanidine and guanidine by luminolenhanced chemiluminescence. Br J Pharmacol 1998; 124: 905–10.
• 16. Giardino I, Fard AK, Hatchell DL, Brownlee M. Aminoguanidine inhibits reactive oxygen species formation, lipid peroxidation, and oxidant-induced apoptosis. Diabetes 1998; 47: 1114–49.
• 17. Babu E, Gopalakrishnan VK, Sriganth IN, Gopalakrishnan R, Sakthisekaran D. Cisplatin induced nephrotoxicity and the modulating effect of glutathione ester. Mol Cell Biochem 1995; 144: 7–11.
• 18. Panagiotopoulos S, O'Brien RC, Bucala R, Cooper ME, Jerums G. Aminoguanidine has an anti-atherogenic effect in the cholesterolfed rabbit. Atherosclerosis 1998; 136(1): 125-31.
• 19. Scaccini C, Chiesa G, Jialal I. A critical assessment of the effects of aminoguanidine and ascorbate on the oxidative modification of LDL: evidence for interference with some assays of lipoprotein oxidation by aminoguanidine. J Lipid Res 1994; 35(6): 1085-92.
• 20. Jedidi I, Thérond P, Zarev S, Cosson C, Couturier M, Massot C, et al. Paradoxical protective effect of aminoguanidine toward low-density lipoprotein oxidation: inhibition of apolipoprotein B fragmentation without preventing its carbonylation. Mechanism of action of aminoguanidine. Biochemistry 2003; 42(38): 11356-65.
• 21. Parlakpinar H, Koc M, Polat A, et al. Protective effect of aminoguanidine against nephrotoxicity induced by amikacin in rats. Urol Res 2004; 32: 278–82.
• 22. Cigremis Y, Parlakpinar H, Polat A, et al. Beneficial role of aminoguanidine on acute cardiomyopathy related to doxorubicin-treatment. Mol Cell Biochem. 2006; 285(1-2): 149-54.
• 23. Atalık KE, Doğan N. Nitrik oksit ve fizyolojik etkileri. Genel Tıp Derg 1997; 7(3): 167-9.
• 24. Parlakpinar H, Ozer MK, Acet A. Effect of aminoguanidine on ischemia-reperfusion induced myocardial injury in rats. Molecular and Cellular Biochemistry 2005; 277: 137–42.
• 25. Adams JA, Wu D, Bassuk J, et al. Nitric oxide synthase isoform inhibition before whole body ischemia reperfusion in pigs: vital or protective? Resuscitation 2007; 74(3): 516-25.
• 26. Parlakpınar H, Örüm MH, Acet A. Kafeik asit fenetil ester (KAFE) ve miyokardiyal iskemi reperfüzyon (Mİ/R) hasarı. İnönü Üniversitesi Sağlık Bilimleri Dergisi 2012; 1: 10-5.
• 27. Moro MA, Darley-Usmar VM, Goodwin DA, et al. Paradoxical fate and biological action of peroxynitrite on human platelets. Proc Natl Acad Sci USA 1994; 91: 6702–6.
• 28. Woolfson RG, Patel VC, Neild GH, Yellon DM. Inhibition of nitric oxide synthesis reduces infarct size by an adenosine-dependent mechanism. Circulation 1995; 91: 1545–51.
• 29. Depre C,Vanoverschelde JL, Goudemant JF, Mottet I, Hue L. Protection against ischemic injury by nonvasoactive concentrations of nitric oxide synthase inhibitors in the perfused rabbit heart. Circulation 1995; 92: 1911–8.
• 30. Bolli R, Patel BS, Jeroudi MO, Lai EK, McCay PB. Demonstration of free radical generation in ‘stunned’ myocardium of intact dogs with the use of the spin trap a-phenyl n-tert-butyl nitrone. J Clin Invest 1988; 82: 476–85.
• 31. Garlick PB, Davies MJ, Hearse DJ, Slater TF. Direct detection of free radicals in the reperfused rat heart using electron spin resonance spectroscopy. Circ Res 1987; 61: 757–60.
• 32. Aydogan H, Gürlek A, Parlakpinar H, Aydogan N, Acet A. The Protective Effect of Aminoguanidine on Random Pattern Skin Flap Survival: An Experimental Study in Rats. Turkiye Klinikleri J Med Sci 2007; 27: 36-43.
• 33. Rubbo H, Darley-Usmar V, Freeman BA. Nitric oxide regulation of tissue free radical injury. Chem Res Toxicol 1996; 9: 809–20.
• 34. Pryor W, Squadrito GL. The chemistry of peroxynitrite: from the reaction of nitric oxide and superoxide. Am J Physiol 1995; 268: 699–722.
• 35. Villa LM, Salas E, Darley-Usmar VM, Radomski MW, Moncada S. Peroxynitrite induces both vasodilation and impaired vascular relaxation in the isolated perfused rat heart. Proc Natl Acad Sci USA 1994; 91: 12383–7.
• 36. Wink DA, Hanbauer I, Krishna MC, DeGraff W, Gamson J, Mitchell JB. Nitric oxide protects against cellular damage and cytotoxicity from reactive oxygen species. Proc Natl Acad Sci USA 1994; 90: 9813–7.
• 37. Yasmin W, Strynadka KD, Schulz R. Generation of peroxynitrite contributes to ischemiareperfusion injury in isolated rat hearts. Cardiovasc Res 1997; 33(2): 422–32.
• 38. Sahna E, Parlakpinar H, Cihan OF, Turkoz Y, Acet A. Effects of aminoguanidine against renal ischaemia–reperfusion injury in rats. Cell Biochem Funct 2006; 24: 137–41.
• 39. Neely MD, Zimmerman L, Picklo MJ, Ou JJ, Morales CR, Montine KS, et al. Congeners of N (alpha)-acetyl-L-cysteine but not aminoguanidine act as neuroprotectants from the lipid peroxidation product 4-hydroxy-2- nonenal. Free Radic Biol Med 2000; 29(10): 1028-36.
• 40. Chowdhury P, Soulsby ME, Scott JL. Effects of Aminoguanidine on Tissue Oxidative Stress Induced by Hindlimb Unloading in Rats. Ann Clin Lab Sci 2009; 39 (1).
• 41. Moncada S, Palmer RM, Higgs EA. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol Rev 1991; 43(2): 109–42.
• 42. Kayaalp SO. Rasyonel tedavi yönünden tıbbi farmakoloji. Cilt 3. Ankara: Feryal Matbaası; 1990.
• 43. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996; 33: 181-94.
• 44. Hasan K, Heesen BJ, Corbett JA, McDaniel ML, Chang K, Allison W, et al. Inhibition of nitric oxide formation by guanidines. Eur J Pharmacol 1993; 249(1): 101–16.
• 45. Nilsson BO, Kockum I, Rosengren E. Effects of aminoguanidine and L-NAME on histamineinduced blood pressure drop in the rat. Acta Physiol Scand 1997; 161(3): 339–44.